## nature portfolio

Corresponding author(s):	Laszlo Urban
Last updated by author(s):	May 20, 2023

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

<b>~</b> .				
St	ำลา	15	ŤΙ	CS

1		
n/a	Cor	nfirmed
	×	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
x		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
x		A description of all covariates tested
	×	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	×	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	×	Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated
,		Our web collection on statistics for biologists contains articles on many of the points above.

## Software and code

Policy information about availability of computer code

Data collection

RDKit version 2021\_03\_5 was used to produce compound SMILES and InChi keys. Datasets downloaded from websites and processed as described in the methods section are available in a Zenodo repository (www.doi.org/10.5281/zenodo.7378746). Datasets were assembled with six Jupyter Notebooks described in the Methods section, and are available on GitHub (www.github.com/Novartis/SPD).

Data analysis

lPython version 7.29 was used to run the provided Jupyter notebooks. Other analyses were performed with R 4.2.1. Plots were prepared in R, Excel (Office 365) and TIBCO Spotfire 11.8. Concentration response curves were produced with GraphPad Prism 9.5.1. Final figures were assembled with Adobe Illustrator 27.6.1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

A Zenodo repository contains results from the Safety Pharmacology Database (SPD), data files used as inputs for the Jupyter notebooks, including downloads from

FAERS and SIDER, ar	nd Supplementar	y Data referenced in the manuscript. The repository is freely available at www.doi.org/10.5281/zenodo.7378746			
Research inv	olving hu	man participants, their data, or biological material			
Policy information a and sexual orientat		vith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> thnicity and racism.			
Reporting on sex ar	nd gender	Not applicable			
Reporting on race, ethnicity, or other socially relevant groupings		Not applicable			
Population characte	eristics	Not applicable			
Recruitment		Not applicable			
Ethics oversight		Not applicable			
Note that full informa	ition on the appro	oval of the study protocol must also be provided in the manuscript.			
Life sciences For a reference copy of t	B he document with	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.  ehavioural & social sciences			
All studies must dis	close on these	points even when the disclosure is negative.			
Sample size	Not applicable.	We analyzed safety pharmacology on data on nearly all marketed drugs.			
Data exclusions	No data was ex	cluded. We provided all data available to us for safety pharmacology assays performed on 1958 marketed drugs.			
Replication	No external replication was performed, as the study analyzed data comprising almost all marketed drugs. We performed 50 folds of leave 20% out cross validation in calibrating logistic regression models, and provide detailed results on all models, including those with low predictive accuracy.				
Randomization	Not applicable. There are no experimental groups being compared in this study.				
Blinding	Not applicable. There are no experimental groups being compared in this study.				
Reporting for specific materials, systems and methods  We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,					
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.					
Materials & experimental systems Methods					
n/a   Involved in the study		n/a   Involved in the study			

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
×	Antibodies	×	ChIP-seq
×	Eukaryotic cell lines	x	☐ Flow cytometry
×	Palaeontology and archaeology	x	MRI-based neuroimaging
×	Animals and other organisms		
X	Clinical data		
×	Dual use research of concern		
×	Plants		